Publications

  1. Slack JL, Dueck AC, Fauble VD, Sproat LO, Reeder CB, Noel P, Khera N, Betcher JA, Klein JL, Leis JF, Adams RH. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch. Biol Blood Marrow Transplant. 2013 Aug; 19(8):1167-74. Epub 2013 May 07.
    View PubMed
  2. Cherington C, Slack JL, Leis J, Adams RH, Reeder CB, Mikhael JR, Camoriano J, Noel P, Fauble V, Betcher J, Higgins MS, Gillette-Kent G, Tremblay LD, Peterson ME, Olsen JJ, Tibes R, Mesa RA. Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase. Leuk Res. 2012 Sep; 36(9):1147-51. Epub 2012 May 11.
    View PubMed
  3. Tibes R, Bogenberger JM, Chaudhuri L, Hagelstrom RT, Chow D, Buechel ME, Gonzales IM, Demuth T, Slack J, Mesa RA, Braggio E, Yin HH, Arora S, Azorsa DO. RNAi screening of the kinome with cytarabine in leukemias. Blood. 2012 Mar 22; 119(12):2863-72. Epub 2012 Jan 20.
    View PubMed
  4. Tallman MS, Kim HT, Montesinos P, Appelbaum FR, de la Serna J, Bennett JM, Deben G, Bloomfield CD, Gonzalez J, Feusner JH, Gonzalez M, Gallagher R, Miguel JD, Larson RA, Milone G, Paietta E, Rayon C, Rowe JM, Rivas C, Schiffer CA, Vellenga E, Shepherd L, Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. Blood. 2010 Dec 16; 116(25):5650-9. Epub 2010 Sep 21.
    View PubMed
  5. Schaefer EW, Loaiza-Bonilla A, Juckett M, DiPersio JF, Roy V, Slack J, Wu W, Laumann K, Espinoza-Delgado I, Gore SD, Mayo P2C Phase II Consortium. A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica. 2009 Oct; 94(10):1375-82.
    View PubMed
  6. Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Garcia-Manero G, Albitar M, Larsen JS, Arora S, Cullen MT, Kantarjian H. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol. 2009 Aug 10; 27(23):3842-8. Epub 2009 Jun 15.
    View PubMed
  7. Wijermans PW, Ruter B, Baer MR, Slack JL, Saba HI, Lubbert M. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res. 2008 Apr; 32(4):587-91. Epub 2007 Sep 18.
    View PubMed
  8. Schiller GJ, Slack J, Hainsworth JD, Mason J, Saleh M, Rizzieri D, Douer D, List AF. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol. 2006 Jun 1; 24(16):2456-64. Epub 2006 May 01.
    View PubMed
  9. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R 3rd, Shen L, Nimer SD, Leavitt R, Raza A, Saba H. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006 Apr 15; 106(8):1794-803.
    View PubMed
  10. Gallagher RE, Schachter-Tokarz EL, Zhou DC, Ding W, Kim SH, Sankoorikal BJ, Bi W, Livak KJ, Slack JL, Willman CL. Relapse of acute promyelocytic leukemia with PML-RARalpha mutant subclones independent of proximate all-trans retinoic acid selection pressure. Leukemia. 2006 Apr; 20(4):556-62.
    View PubMed
  11. Shaukat A, Bakri F, Young P, Hahn T, Ball D, Baer MR, Wetzler M, Slack JL, Loud P, Czuczman M, McCarthy PL, Walsh TJ, Segal BH. Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: clinical, radiologic, and pathologic characteristics. Mycopathologia. 2005 Feb; 159(2):181-8.
    View PubMed
  12. Iyer RV, Sait SN, Matsui S, Block AW, Barcos M, Slack JL, Wetzler M, Baer MR. Massive hyperdiploidy and tetraploidy in acute myelocytic leukemia and myelodysplastic syndrome. Cancer Genet Cytogenet. 2004; 148(1):29-34.
    View PubMed
  13. Dibo I, Pillai SK, Gold HS, Baer MR, Wetzler M, Slack JL, Hazamy PA, Ball D, Hsiao CB, McCarthy PL Jr, Seagal BH. Linezolid-resistant Enterococcus faecalis isolated from a cord blood transplant recipient. J Clin Microbiol. 2004; 42(4):1843-5.
    View PubMed
  14. Hahn T, Alam AR, Lawrence D, Ford L, Baer MR, Bamback B, Bernstein ZP, Czuczman MS, Silva J, Slack JL, Wetzler M, Becker J, McCarthy PL Jr. Thrombotic microangiopathy after allogeneic blood and marrow transplantation is associated with dose-intensive myeloablative conditioning regiments, unrelated donor, and methylprednisone T-cell depletion. Transplantation. 2004; 78(10):1515-22.
    View PubMed
  15. Hahn T, Rondeau C, Shaukat A, Jupudy V, Miller A, Alam AR, Baer MR, Bambach B, Bernstein Z, Chanan-Khan AA, Czuczman MS, Slack J, Wetzler M, Mookerjee BK, Silva J, McCarthy PL Jr. Acute renal failure requiring dialysis after allogeneic blood and marrow transplantation identifies very poor prognosis patients. Bone Marrow Transplant. 2003 Aug; 32(4):405-10.
    View PubMed
  16. Gallagher RE, Yeap BY, Bi W, Livak KJ, Beaubier N, Rao S, Bloomfield CD, Appelbaum FR, Tallman MS, Slack JL, Willman CL. Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood. 2003 Apr 1; 101(7):2521-8.
    View PubMed
  17. Wetzler M, McElwain BK, Stewart CC, Blumenson L, Mortazavi A, Ford LA, Slack JL, Barcos M, Ferrone S, Baer MR. HLA-DR antigen-negative acute myeloid leukemia. Leukemia. 2003 Apr; 17(4):707-15.
    View PubMed
  18. List A, Beran M, DiPersio J, Slack J, Vey N, Rosenfeld CS, Greenberg P. Opportunities for trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. Leukemia. 2003; 8:1499-1507.
  19. Hahn T, Bunworasate U, George MC, Bir AS, Chinratanalaa W, Alam AR, Bambach B, Baer MR, Slack JL, Wetzler M, Becker JL, McCarthy PL Jr. use of nonvolume-reduced (unmanipulated after thawing) umbilical cord blood stem cells for allogeneic transplantation results in safe engraftment. Bone Marrow Transpl. 2003; 32(2):145-50.
  20. Shaukat A, Benekli M, Vladutiu GD, Slack JL, Wezler M, Baer MR. Simvastat-influconazole causing rhabdomyloysis. Ann Pharmacother. 2003; 37(7-8):1032-5.
    View PubMed
  21. Slack JL, Waxman S, Tricot G, Tallman MS, Bloomfield CD. Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide. Oncologist. 2002; 7 Suppl 1:1-13.
    View PubMed
  22. Slack JL, Bi W, Livak KJ, Beaubier N, Yu M, Clark M, Kim SH, Gallagher RE, Willman CL. Pre-clinical validation of a novel, highly sensitive assay to detect PML-RARalpha mRNA using real-time reverse-transcription polymerase chain reaction. J Mol Diagn. 2001 Nov; 3(4):141-9.
    View PubMed
  23. Simon M, Hahn T, Ford LA, Anderson B, Swinnich D, Baer MR, Bambach B, Bernstein SH, Bernstein ZP, Czuczman MS, Slack JL, Wetzler M, Herzig G, Schriber J, McCarthy PL Jr. Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin. Bone Marrow Transplant. 2001 Mar; 27(6):627-33.
    View PubMed
  24. Slack JL, Rusiniak ME. Current issues in the management of acute promyelocytic leukemia. Ann Hematol. 2000 May; 79(5):227-38.
    View PubMed
  25. Rusiniak ME, Yu M, Ross DT, Tolhurst EC, Slack JL. Identification of B94 (TNFAIP2) as a potential retinoic acid target gene in acute promyelocytic leukemia. Cancer Res. 2000 Apr 1; 60(7):1824-9.
    View PubMed
  26. Slack JL, Willman CL, Andersen JW, Li YP, Viswanatha DS, Bloomfield CD, Tallman MS, Gallagher RE. Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARalpha isoform: results from intergroup protocol 0129. Blood. 2000 Jan 15; 95(2):398-403.
    View PubMed
  27. Schriber J, Milk B, Shaw D, Christiansen N, Baer M, Slack J, Tezcan H, Wetzler M, Herzig G. Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation. Bone Marrow Transplant. 1999 Dec; 24(12):1311-4.
    View PubMed
  28. Slack JL. Biology and treatment of acute progranulocytic leukemia. Curr Opin Hematol. 1999 Jul; 6(4):236-40.
    View PubMed
  29. Slack JL. The biology and treatment of acute progranulocytic leukemia. Curr Opin Oncol. 1999 Jan; 11(1):9-13.
    View PubMed
  30. Alidina A, Lawrence D, Ford LA, Baer MR, Bambach B, Bernstein SH, Czuczman MS, Slack JL, Spangenthal E, Wetzler M, Barcos MP, Proulx GM, Anderson B, McCarthy PL Jr. Thiotepa-associated cardiomyopathy during blood or marrow transplantation: association with the female sex and cardiac risk factors. Biology of Blood & Marrow Transplantation. 1999; 5(5):322-7.
    View PubMed
  31. Slack JL, Gallagher RE. The molecular biology of acute promyelocytic leukemia. Cancer Treat Res. 1999; 99:75-124.
    View PubMed
  32. Wetzler M, Bernstein SH, Baumann H, Fries KM, Stewart C, Blumenson L, Baer MR, Herzig GP, Bloomfield CD, Slack JL. Expression and function of the megakaryocyte growth and development factor receptor in acute myeloid leukemia blasts. Leukemia & Lymphoma. 1998 Aug; 30(5-6):415-31.
    View PubMed
  33. Slack JL, Yu M. Constitutive expression of the promyelocytic leukemia-associated oncogene PML-RARalpha in TF1 cells: isoform-specific and retinoic acid-dependent effects on growth, bcl-2 expression, and apoptosis. Blood. 1998 May 1; 91(9):3347-56.
    View PubMed
  34. Slack JL. Recent advances in the biology and treatment of acute promyelocytic leukemia. J Clin Oncol. 1998; 16:54-65.
  35. Gallagher RE, Willman CL, Slack JL, Andersen JW, Li YP, Viswanatha D, Bloomfield CD, Appelbaum FR, Schiffer CA, Tallman MS, Wiernik PH. Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. Blood. 1997 Aug 15; 90(4):1656-63.
    View PubMed
  36. Slack JL, Arthur DC, Lawrence D, Mrozek K, Mayer RJ, Davey FR, Tantravahi R, Pettenati MJ, Bigner S, Carroll AJ, Rao KW, Schiffer CA, Bloomfield CD. Secondary cytogenetic changes in acute promyelocytic leukemia--prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study. J Clin Oncol. 1997 May; 15(5):1786-95.
    View PubMed
  37. Heinonen K, Rao PN, Slack JL, Cruz J, Bloomfield CD, Mrozek K. Isochromosome 12p in two cases of acute myeloid leukaemia without evidence of germ cell tumour. Br J Haematol. 1996 Jun; 93(3):677-80.
    View PubMed
  38. Slack JL, Parker MI, Bornstein P. Transcriptional repression of the alpha 1(I) collagen gene by ras is mediated in part by an intronic AP1 site. J Cell Biochem. 1995 Jul; 58(3):380-92.
    View PubMed
  39. Slack JL, Bornstein P. Transformation by v-src causes transient induction followed by repression of mouse thrombospondin-1. Cell Growth & Differentiation. 1994 Dec; 5(12):1373-80.
    View PubMed
  40. Slack JL, Liska DJ, Bornstein P. Regulation of expression of the type I collagen genes. Am J Med Genet. 1993 Jan 15; 45(2):140-51.
    View PubMed
  41. Slack JL, Parker MI, Robinson VR, Bornstein P. Regulation of collagen I gene expression by ras. Mol Cell Biol. 1992 Oct; 12(10):4714-23.
    View PubMed
  42. Slack JL, Liska DJ, Bornstein P. An upstream regulatory region mediates high-level, tissue-specific expression of the human alpha 1(I) collagen gene in transgenic mice. Mol Cell Biol. 1991 Apr; 11(4):2066-74.
    View PubMed
  43. Slack JL, Nemunaitis J, Andrews DF 3rd, Singer JW. Regulation of cytokine and growth factor gene expression in human bone marrow stromal cells transformed with simian virus 40. Blood. 1990 Jun 15; 75(12):2319-27.
    View PubMed
  44. Liska DJ, Slack JL, Bornstein P. A highly conserved intronic sequence is involved in transcriptional regulation of the alpha 1(I) collagen gene. Cell Regul. 1990 May; 1(6):487-98.
    View PubMed